glp-1 receptor agonists and cancer risk in adults with obesity show anti-cancer benefits beyond weight loss The effect of GLP-1R agonists
Description
Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism

Exendin-4 degrades more slowly than the human form of GLP-1, lasting for hours instead of minutes

The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo

Adapted from Kadowaki et al
